Novo Nordisk is increasing its adoption of artificial intelligence through AWS to bolster drug discovery and research processes. This collaboration designates AWS as the company's primary cloud service provider and introduces a new co-innovation hub in London. The firm reports that over 25,000 staff members have engaged with its generative AI platform across more than 2,500 applications. AWS has indicated that one AI solution has minimized certain clinical documentation efforts by over 90%. This new alliance will leverage AI agents and biological models to pinpoint drug targets, formulate therapies, and analyze research data, potentially accelerating drug development timelines.
Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools.
ai-generated
